Vimarsana
Biggest News Aggregation in the World

Page 4 - John Lacey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Lacey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Lacey Today - Breaking & Trending Today

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024 - Vimarsana News

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement - Vimarsana News

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates - Vimarsana News

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...

Proposed bill aims to make package theft a felony - Vimarsana News

Proposed bill aims to make package theft a felony

Porch pirate theft is increasing and now Florida lawmakers want to crack down on the crime.

Source: nbc-2.com
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease - Vimarsana News

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

- Proof-of-concept study is initial step toward goal of identifying more efficient CD34+ HSC mobilization regimen for patients with sickle cell disease choosing gene therapy - TEL AVIV, Israel,...